Immuno-Oncology (I-O) research is the investigation of innovative approaches that aim to harness the body’s natural immune response to fight cancer. For many years, Bristol-Myers Squibb has been committed to advancing this fundamentally different approach to cancer research.
Bristol-Myers Squibb continues to build upon our past discoveries and advance our current research. These advances are bringing to light unique considerations and distinctive characteristics that may shape future research. The potential of I-O research continues to expand, driven by the many patients with advanced cancer who await the offer of renewed hope and the potential of a longer life.
From revealing the power of the immune system in cancer, to realizing its broad
potential—Bristol-Myers Squibb is at the forefront of Immuno-Oncology research.
-
Modulating PD-1 Reinvigorates Exhausted T Cells
T-cell exhaustion induced by the PD-1 pathway drives immune escape in cancer.
READ MORE > -
Immune Pathways Combine to Refine Response
Signaling pathways can work in combination to modulate the activity of effector cells.
READ MORE > -
I-O Biomarkers Are Indicators of
Immune ActivityResearch seeks to characterize the relationship between the immune system, the tumor and its microenvironment, and the host.
READ MORE > -
Recognize Pseudo-Progression
Pseudo-progression may reflect development of antitumor immunity.
READ MORE >
I-O TalksView Immuno-Oncology research in various tumor types
I-O in DepthDownload in-depth information for you and your patients